BioCryst up on preclinical HCV data

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) gained $0.44 (12%) to $4.11 on Wednesday after reporting "favorable" preclinical data for HCV product BCX5191. BioCryst said in vitro and in vivo studies ...